GDx Staging System is successful in RNFL damage classification

Article

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage.

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage, according to a study published in the Journal of Glaucoma.

Dr Paolo Brusini et al., Department of Ophthalmology, Azienda Ospedaliero-Universitaria, Udine, Italy, conducted 320 GDx VCC tests on 84 healthy patients and 236 patients suffering from ocular hypertension or chronic open angle glaucoma. Additionally, the sensitivity and specificity of the GDx was measured in 161 patients with ocular hypertension or chronic open angle glaucoma and 34 normal patients.

The findings showed that sensitivity and the specificity of the GDx were significantly high at 88.2% and 100%, respectively. The results of clinical classification of glaucoma and the Glaucoma Staging System 2 were strongly correlated.

The GDx Staging System is a quick and effective method for classifying RNFL damage, especially for inexperienced ophthalmologists.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.